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Abstract
Background: Peutz-Jeghers syndrome (PJS) is a rare multi-organ cancer syndrome and
understanding its genetic basis may help comprehend the molecular mechanism of familial cancer.
A number of germ line mutations in the STK11 gene, encoding a serine threonine kinase have been
reported in these patients. However, STK11 mutations do not explain all PJS cases. An earlier study
reported absence of STK11 mutations in two Indian families and suggested another potential locus
on 19q13.4 in one of them.
Methods: We sequenced the promoter and the coding region including the splice-site junctions
of the STK11 gene in 16 affected members from ten well-characterized Indian PJS families with a
positive family history.
Results: We did not observe any of the reported mutations in the STK11 gene in the index patients
from these families. We identified a novel pathogenic mutation (c.790_793 delTTTG) in the STK11
gene in one index patient (10%) and three members of his family. The mutation resulted in a frame-
shift leading to premature termination of the STK11 protein at 286th codon, disruption of kinase
domain and complete loss of C-terminal regulatory domain. Based on these results, we could offer
predictive genetic testing, prenatal diagnosis and genetic counselling to other members of the
family.
Conclusion: Ours is the first study reporting the presence of STK11 mutation in Indian PJS
patients. It also suggests that reported mutations in the STK11 gene are not responsible for the
disease and novel mutations also do not account for many Indian PJS patients. Large-scale genomic
deletions in the STK11 gene or another locus may be associated with the PJS phenotype in India
and are worth future investigation.
Background
Peutz-Jeghers syndrome (PJS; MIM 175200) is a rare,
autosomal dominant multi-organ cancer syndrome
involving primarily the gastrointestinal tract, pancreas,
luminal organs, female and male reproductive organs and
the lungs [1,2]. The disease is characterized by hamar-
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lesions. Linkage studies have mapped the disease to
19p13.3 [3,4] and germ line mutations in the serine thre-
onine kinase 11 (STK11; NM_000455.4) gene at this locus
have been identified as a major cause of PJS [5-7]. STK11
is a known tumor suppressor and several studies have
reported loss of the normal allele in the polyps from these
patients [8-10]. Since growth of the hamartomatous pol-
yps leads to malignancy, it is believed that inactivation of
STK11 gene results in disruption of a fundamental growth
control mechanism within somatic cells that have high
proliferative capacity [11]. Penetrance of the gene is varia-
ble causing varied phenotypic manifestations among
patients, which to a certain extent is correlated with the
nature of the STK11 gene mutations [7,12]. To date, more
than 140 different mutations in the STK11 gene have been
reported and most of them result in a truncated protein
but some missense or small in-frame deletions have also
been reported [11]. Recent studies have reported large
genomic deletions in the STK11 gene in about 30% of PJS
patients and add to the mounting evidence for there being
only one gene associated with this syndrome [13,14].
The disease has hardly been studied in the Indian popula-
tion. The only study reported to date investigated two
families and failed to find any mutation in the STK11
gene [15]. Rather, the authors identified a potential sec-
ond locus (19q13.4) in one Indian family [15]. In the
present study, we have recruited 10 well-characterized
Indian PJS families and attempted to study the nature and
importance of STK11 mutations in them. We have
explored the 5' upstream region for putative promoter
sequences and sequenced the promoter and complete
coding region of the STK11 gene including the flanking
intron-exon boundaries. We report a novel mutation in
the STK11 gene in an Indian family and its application in
prenatal diagnosis and genetic counseling for the family.
Our study shows that reported mutations in the STK11
gene do not account for Indian PJS patients and adds to
the spectrum of mutational heterogeneity associated with
Peutz Jeghers syndrome. It also stresses on the role of
large-scale genomic deletions in the STK11 gene or
involvement of another PJS locus.
Methods
Subjects and clinical history
The classification of individuals as affected was based on
the established criteria for diagnosis of PJS such as pres-
ence of mucocutaneous hypermelanocytic lesions along
with more than three histopathologically proven hamar-
tomatous polyps and a positive family history [1,2,16,17].
All ten families recruited in the study were examined by
gastroenterologists (DNR and GVR) at the Asian Institute
of Gastroenterology, Hyderabad and fulfilled the above-
mentioned criteria. Peripheral blood samples were col-
lected from the affected and unaffected members of these
families (16 affected and 18 unaffected) after signing
informed consent forms. The personal details, clinical
symptoms and medical history of the patients and other
family members were noted in a questionnaire at the time
of collection of blood samples. In the family (Fig 1.1) that
we report here, the proband was a 26-year-old man (II:2),
evaluated for constipation, weakness and hyperpigmenta-
tion of lips, palms and digits. Of all members of the fam-
ily, he had the earliest age of onset of symptoms at 7 yrs.
He was first diagnosed to have intestinal polyps by upper
GI endoscopy and colonoscopy at the age of 11 yrs. On
recent investigation using capsule endoscopy, he was
found to carry hundreds of polyps measuring 1 × 1.5 cm
(app.) throughout the intestinal tract without any evi-
dence of stricture. He had severe manifestations of the dis-
ease and had undergone polypectomy three times. In
contrast, his elder sister (II:1) had mild disease with a rel-
atively late age of onset at 15 years. She could not be
screened for intestinal polyps at the time of this study in
view of her being pregnant. The disease has been mildest
in the youngest sister (aged 23 yrs) (II:3), who did not
have any major complaints except for occasional
instances of constipation. On colonoscopy, she was found
to carry 25–30 polyps mainly in the descending and trans-
verse colon and few in the rectum. Her small intestine
could not be analyzed as she refused to give consent for
upper GI endoscopy and capsule endoscopy. Their father
had the first symptoms of disease at age 27, underwent his
first polypectomy at 42 years and expired of severe intesti-
nal bleeding during the course of our study. This indicates
phenotypic heterogeneity, classically associated with
Peutz Jeghers syndrome. Their mother (I:2) did not have
history of any gastrointestinal problems. Polyps from all
the patients were subjected to histopathological examina-
tion and mutation analysis for the detection of a specific
mutation in the STK11 gene.
Characterization and analysis of the 5'UTR region of 
STK11
Promoter region of the STK11 gene is not well character-
ized except in a recent report [18]. We predicted a putative
promoter region with the help of Transcription factor
binding site (TFBS) prediction programmes, Transplorer
(Biobase Biological Databases, Wolfenbuttel, Germany)
and Proscan v1.7, [19] which indicated the presence of
promoter elements within the regions -876 to -1126 and -
1321 to -1571, position 1145787 to 1146037 and
1145341 to 1145591 respectively (NT_011255). Trans-
plorer predicted 48 TFBSs within the region -1090 to -
1472 earlier analyzed by Hearle et al [18]. Proscan pre-
dicted 44 TFBS in the processed sequence of 2271 base
pairs upstream of the STK11 initiation signal between
positions -876 to -1126 and -1322 to -1571. Promoter ele-
ments predicted by each of the program were aligned toPage 2 of 6
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A, shows the pedigree chart of the Indian PJS family showing the novel 4 bp deletion (c.790_793delTTTG) in the STK11 geneFigure 1
A, shows the pedigree chart of the Indian PJS family showing the novel 4 bp deletion (c.790_793delTTTG) in the STK11 gene. 
The proband is indicated by an arrow. The younger sister (II.3) did not show the classical symptoms of PJS and hence is repre-
sented with a "?". B, shows the electropherogram presenting a heterozygous 4 bp deletion (-TTTG) at position 790 
(c.790_793delTTTG) of the STK11 gene as indicated by the arrow. The deletion mutation leads to a premature stop codon at 
286, truncating the protein leading to partial loss of its catalytic kinase domain and complete loss of the regulatory domain.
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moter.
Genetic analysis
Genomic DNA was isolated from blood and polyp tissue
samples following standard protocols [20]. All nine exons
with the splice site junctions and the predicted promoter
region were PCR amplified with primers designed using
the Genetool software. Predicted PCR products were sub-
jected to searches of the genome using the BLAST program
(21) to confirm specificity of primers (Table 1). Purified
PCR products were analyzed by bi-allelic direct DNA
sequencing using the Big Dye v3.1 Terminator Cycle
Sequencing Ready Reaction Kit in conjunction with an
ABI 3730 automated genetic analyzer (Applied Biosys-
tems, Foster City, USA). Sequence analysis was repeated to
confirm the mutation and its status in the members of the
reported family. 100 normal individuals were screened for
the novel mutation by sequencing. Both Centre for Cellu-
lar and Molecular Biology and Asian Institute of Gastroen-
terology have their Institutional Ethics Committee, which
approved the study following the guidelines for research
on human subjects formulated by the Indian Council of
Medical Research, Ministry of Health, Government of
India, New Delhi. The patients were explained various
diagnostic procedures and the procedure and utility of
genetic study. They were also explained about the possi-
bility of failure to detect any mutation in the family.
Results and discussion
An earlier study by Mehenni et al., failed to detect muta-
tions in STK11 gene in two multi-generational Indian
Peutz-Jeghers syndrome families [15]. We sequenced the
coding and the promoter regions of the STK11 gene in 16
patients from ten Indian PJS families. We did not find the
reported mutations in any patient from these families but
detected a novel mutation in one family with multiple
patients in two generations. The proband in this family
was found to carry a novel heterozygous 4 base pair dele-
tion, TTTG at nucleotide position 790 in exon 6 of the
STK11 gene (c.790_793delTTTG), which was also identi-
fied in heterozygous state in the polyps removed from his
jejunum (Fig 1.2). As expected of any pathogenic STK11
frame-shift mutation, we did not observe this mutation in
200 normal chromosomes. Mutation analysis of other
family members showed the affected father and the elder
sister to be heterozygous for this mutation, both in
peripheral leucocytes and the polyp tissue. The younger
sister also carried the same mutation as observed in other
affected family members, but she did not show the classi-
cal disease phenotype. The mutation creates a frame-shift
after codon 264 resulting in premature termination of the
433 amino acid protein at 286th codon. This leads to a par-
tial loss of the kinase domain and a complete loss of the
C-terminal regulatory domain (CRD). Similar 4 base pair
deletions have been reported in tumor suppressor genes
such as c.962_965delCTCA in BRCA1 and
c.4888_4891delGTTA in APC genes associated with dis-
eases such as breast carcinoma and familial adenomatous
polyposis coli (FAP) respectively [22,23]. These mutations
result in truncated proteins that are non-functional due to
the loss of activity of critical functional domains.
STK11 protein mainly comprises of three major domains,
the N-terminal non-catalytic domain containing the
nuclear localization signal, the catalytic kinase domain
and the C-terminal regulatory domain [24]. Although
exact function of STK11 largely remains unknown, studies
suggest its role in cell signaling and apoptosis [25].
Expression of majority of mutant STK11 proteins and
assessment of their phosphorylation activity has revealed
a loss of the kinase activity in STK11 mutants suggesting
that loss of its kinase activity is probably responsible for
development of the PJS phenotype [26]. We hypothesize
that the deletion mutation in the reported family may
lead to an altered kinase activity of the protein as a result
of partial loss of the kinase domain. The resultant mutant
protein is also deficient in its C-terminal domain, which
is known to serve as a regulatory domain mediating
dynamic interactions with several classes of proteins and
promoting sub-cellular targeting apart from controlling
cell polarity [27]. Mutations leading to partial or complete
loss of the C-terminal domain of STK11, as observed in
the present case, lead to loss of cell polarity and hamar-
toma formation as a result of inappropriate overgrowth of
differentiated cells, which have lost their ability to regu-
late their polarity [27]. In the background of these obser-
vations, we propose that the deletion mutation in the
Table 1: Primers for exon-specific sequencing of STK11 gene
Exon Forward primer (5'-3') Reverse primer (5'-3')
5' UTR GCGTTTCTCTTTCCCCTGGTC TGCCCTCAGCGTCCGGTCC
1 CACAAGGAAGGACCGCTCAC CCGCTGCGACAACTGGCCTT
2 & 3 AACTCACAGCTTCTCTCTAG AAAACTTGGGCCTTCATGTC
4 & 5 GCTGGGCCTGTGGTGTTTGG GACGGGCCAGGCTGCACTTC
6 & 7 GCAGCCACGGGACGCCTCT CCACCACGCCCTGCTCTAG
8 CCCTTGCACGGCCTGGTCC TGGGACATCCTGGCCGAGT
9 TGGATACACCTGGGCCTGAC GGGCTATGCTCACGGCTGGCPage 4 of 6
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tion through suppression of growth arrest, apoptosis and
dysregulation of AMP-activated protein kinase (AMPK)
pathway leading to hyperactive mammalian target of
rapamycin (mTOR) signaling [28].
Since development of tumors in most cases is a result of
multiple mutations, PJS patients may have mutations in
some other genes linking the STK11 gene to its final target
for cell signaling, which may also explain phenotypic var-
iability of the disease. Phenotypic heterogeneity and lack
of genotype-phenotype correlation is a feature of Peutz
Jeghers syndrome, which appears to be true for the
c.790_793delTTTG mutation identified in the present
study. Although, the younger sister was a carrier of the
mutation, she did not have any symptoms of the disease.
On colonoscopy, we found multiple intestinal polyps
including three in the rectum. The polyps showed the
characteristic histological features of PJS polyps, which,
included irregularly dilated mucous glands with splaying
of muscularis mucosa into the lamina propria and
absence of dysplastic changes and also harboured the
deletion mutation in heterozygous state. Taking help of
this information, we advised the elder sister to undergo
prenatal diagnosis by chorion villus sampling. Fortu-
nately, the fetus was identified to be normal for the dele-
tion mutation in the STK11 gene and the pregnancy was
continued.
The patients recruited in this study were identified using
well-established clinical diagnostic criteria for PJS
(16,17). These included more than three histopathologi-
cally proven PJS polyps together with classical mucocuta-
neous pigmentation and a positive family history (16,17).
Therefore, the possibility that these patients are affected
with hamartomatous polyposis syndromes other than PJS
is highly unlikely. Such syndromes include juvenile poly-
posis coli, Cowden syndrome or Bannayan-Ruvalcaba-
Riley syndrome but none of these are characterized by typ-
ical pigmentation seen in PJS patients. The reason for
absence of STK11 mutations in other patients is not clear,
however it can be suspected that large-scale genomic dele-
tions/insertions, undetectable by direct DNA sequencing
or intronic or promoter changes in the STK11 gene may be
responsible for the disease. Involvement of a heterogene-
ous minor PJS locus is another interesting possibility as
suggested by Mehenni et al., who observed a high LOD
score at 19q13.4 in one Indian family but proposed it to
be due to chance only [15].
Conclusion
We conclude that reported mutations in the STK11 gene
are not responsible for Peutz- Jeghers syndrome in Indian
patients, but novel mutations too, may not explain the
disease in majority of them. Our study is the first report
showing presence of a mutation in the STK11 gene in an
Indian PJS family. However, large genomic deletions or
linkage to another locus as proposed by Mehenni et al. are
definite possibilities [15]. Extensive analysis of the STK11
gene using approaches such as multiple ligation depend-
ent probe amplification may explain the disease in the
remaining families. In the absence of these, genome-wide
scan on these families may help to identify another PJS
locus.
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